Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2020 Dec 2;20(1):316.
doi: 10.1186/s12890-020-01351-z.

Clinical profiles of subclinical disease among pulmonary tuberculosis patients: a prospective cohort study in South Korea

Affiliations
Observational Study

Clinical profiles of subclinical disease among pulmonary tuberculosis patients: a prospective cohort study in South Korea

Jinsoo Min et al. BMC Pulm Med. .

Abstract

Background: Subclinical tuberculosis (TB) is a potential target for public health intervention because its early identification may reduce TB transmission. We aimed to describe the clinical and laboratory findings of subclinical disease among pulmonary TB patients and compared treatment outcomes for subclinical and active diseases.

Methods: In this prospective cohort study, we enrolled adult patients aged ≥ 19 years with pulmonary TB between 2016 and 2018. Subclinical TB was defined as radiographic or microbiologic test results consistent with TB without clinical symptoms. We implemented a two-stage symptom assessment using a predefined TB symptom checklist. Demographic, clinical, and laboratory data were compared between subclinical and active diseases using multivariable binary logistic regression analysis. We evaluated treatment outcomes in the drug-susceptible cohort.

Results: Among 420 enrolled patients, 81 (19.3%) had subclinical TB. Multivariable analysis showed that age < 65 years was the only variable significantly associated with subclinical disease. Subclinical disease had a significantly lower proportion of acid-fast bacilli smear and culture positivity and multiple lobe involvement compared to active disease. The white blood cell counts, platelet counts, and C-reactive protein levels were significantly higher among patients with active disease than among those with subclinical disease. Among 319 patients with treatment success in the drug-susceptible cohort, six (1.9%) recurrent cases were identified, and all were active disease. Patients with subclinical disease had a higher proportion of favourable outcomes; however, its odds ratio was insignificant.

Conclusions: Nearly one-fifth of tuberculosis cases were subclinical in South Korea. Despite its milder clinical presentation and lower level of inflammatory markers, the treatment outcomes of subclinical TB were not significantly different from that of active disease.

Keywords: Bronchoscopy; Computed tomography; Pulmonary tuberculosis; Subclinical disease; Symptom.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig. 1
Fig. 1
Flow chart of patient enrollment and final outcomes of drug-susceptible cohort. TB tuberculosis. 1Drug-susceptible cohort comprises patients who have positive culture results susceptible with both isoniazid and rifampin and who are clinically diagnosed with tuberculosis without microbiological evidence. 2Inactive TB was diagnosed when a follow-up chest radiography showed no changes of pulmonary lesions or a previous chest images revealed unchanged lesions without microbiological evidence of Mycobacterium tuberculosis infection
Fig. 2
Fig. 2
Mycobacterium tuberculosis culture results stratified by number of lobe involvement on chest computed tomography and additional performance of bronchoscopy. TB tuberculosis, CT computed tomography, MTBc Mycobacterium tuberculosis

References

    1. Cohen A, Mathiasen VD, Schon T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54:1900655. doi: 10.1183/13993003.00655-2019. - DOI - PubMed
    1. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO's new end TB strategy. Lancet. 2015;385:1799–1801. doi: 10.1016/S0140-6736(15)60570-0. - DOI - PubMed
    1. Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, et al. Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection. Clin Microbiol Rev. 2018;31:e00021–e118. doi: 10.1128/CMR.00021-18. - DOI - PMC - PubMed
    1. Esmail H, Barry CE, 3rd, Young DB, Wilkinson RJ. The ongoing challenge of latent tuberculosis. Phil Trans R Soc B. 2014;369:20130437. doi: 10.1098/rstb.2013.0437. - DOI - PMC - PubMed
    1. Global Tuberculosis Report. Geneva, Switzerland: World Health Organization; 2018.

Publication types

MeSH terms